glp-1 and eating disorders Role of GLP-1A Receptor Agonists in New research from our team

About 59.8% of ESRD patients are White, 33.2% are Black, 3.6% are Asian, and 1.6% are Native American

PMID: 185 FukushimaAAizakiYSakumaK

Read More Featured Activity || By Administrator 3 / 4 September 2025 Makati City The Food and Drug Administration (FDA), through its Director General Paolo S

A study including both in vivo and in vitro experiments has reported that Tan-IIA can prevent lipopolysaccharide (LPS)-induced brain damage by activating the Nrf2 signaling pathway and rescuing tight-junction proteins in microvascular endothelial cells, thereby inhibiting oxidative stress and inflammatory responses to protect the BBB (Wang et al., 2022)

Exendin-4, a Glucagon-like Peptide-1 Receptor Agonist, Reduces Intimal Thickening after Vascular Injury